Hawaii 2024 Regular Session

Hawaii Senate Bill SB446

Introduced
1/20/23  
Refer
1/25/23  
Introduced
1/20/23  
Report Pass
2/17/23  
Refer
1/25/23  
Report Pass
2/17/23  

Caption

Relating To Prescription Digital Therapeutics.

Impact

If implemented, this pilot program could significantly influence the state's approach to treating substance use disorders. It may enhance outreach to individuals struggling with these issues and provide innovative treatment options. The law would require a thorough investigation into existing healthcare structures and their adaptability to incorporate these digital solutions, ensuring that care providers are equipped to deliver effective treatment and monitoring.

Summary

Senate Bill 446 aims to address substance use disorders and opioid use disorders within the State of Hawaii by exploring the feasibility of a pilot program that integrates prescription digital therapeutics (PDTs) approved by the federal Food and Drug Administration into outpatient treatment programs. The bill mandates the Department of Health to conduct a comprehensive study to assess various aspects necessary for the implementation of such a program. This includes evaluating potential financial impacts, demographic needs of affected populations, and costs versus benefits of incorporating FDA-approved digital therapeutics into existing treatment modalities.

Conclusion

Senate Bill 446 represents a proactive step toward modernizing treatment options for individuals suffering from substance use and opioid use disorders in Hawaii. Its successful enactment hinges on careful planning, collaboration among stakeholders, and addressing potential barriers to implementation.

Contention

While the bill enjoys the support of those seeking to innovate treatment options for substance use disorders, it may encounter challenges related to the integration of new technologies in traditional care frameworks. There may be concerns regarding the privacy and security of health data, as well as the readiness of current healthcare providers to adopt new digital therapeutics. Moreover, discussions may arise about the allocation of funding and resources necessary to implement the pilot program effectively, especially in light of varying health system capabilities across the state.

Companion Bills

HI SB446

Carry Over Relating To Prescription Digital Therapeutics.

Previously Filed As

HI SB446

Relating To Prescription Digital Therapeutics.

HI HB2451

Prescription digital therapeutics; pilot program

HI SB723

Access to Prescription Digital Therapeutics Act of 2023

HI HB3288

Access to Prescription Digital Therapeutics Act of 2025

HI HB1458

Access to Prescription Digital Therapeutics Act of 2023

HI SB139

To Require That The Arkansas Medicaid Program Cover Authorized Prescription Digital Therapeutics.

HI HB813

Maryland Medical Assistance Program – Prescription Digital Therapeutics

HI SB1702

Access to Prescription Digital Therapeutics Act of 2025

HI SB441

Maryland Medical Assistance Program - Prescription Digital Therapeutics

HI HF771

Medical assistance coverage expanded to include prescription digital therapeutics.

Similar Bills

AZ HB2451

Prescription digital therapeutics; pilot program

HI SB446

Relating To Prescription Digital Therapeutics.

CA AB1011

Health care coverage: substance use disorders.

CA SB854

Health care coverage: substance use disorders.

AR SB139

To Require That The Arkansas Medicaid Program Cover Authorized Prescription Digital Therapeutics.

VA SB1081

Optometry; dissolves TPA-Formulary and TPA-Formulary Committee.

VA HB1898

Optometry; TPA-Formulary; TPA-Formulary Committee; dissolution.

CA AB407

Optometry: assistants and scope of practice.